Further, increased secretion of IL-6 has been linked to resistance to bortezomib in MM and to etoposide and cisplatin in hormone-independent prostate carcinomas (Borsellino et al., 1995; Frassanito et al., 2001; Voorhees et al., 2007). Here, IL6 is linked to Miyoshi myopathy.